Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The role of visceral adiposity in the severity of COVID-19: Highlights from a unicenter cross-sectional pilot study in Germany

Antonia Petersen,⁎ Keno Bressem, Jakob Albrecht, Hans-Martin Thieß, Janis Vahldiek, Bernd Hamm, Marcus R. Makowski,①⁎⁎, Alexandra Niehues, Stefan M. Niehues, Lisa C. Adams

Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Radiology, Hindenburgdamm 30, 12203 Berlin, Germany
Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Department of Radiology, Charitéplatz 1, 10117 Berlin, Germany
Charité – Universitätsmedizin Berlin, Campus Charité Mitte, Department of Diagnostic and Interventional Radiology, 81675 Munich, Germany
Berlin Institute of Health (BIH), 10178 Berlin, Germany

⁎ Corresponding author at: Campus Benjamin Franklin, Department of Radiology, Hindenburgdamm 30, 12203 Berlin, Germany.
⁎⁎ Corresponding author at: Campus Charité Mitte, Department of Radiology, Charitéplatz 1, 10117 Berlin, Germany.
E-mail address: antonia.petersen@charite.de (A. Petersen).

Article history:
Received 15 May 2020
Received in revised form 4 July 2020
Accepted 9 July 2020

Keywords: COVID-19 Obesity Overweight Quantification of adipose tissue Visceral adipose tissue

A B S T R A C T

Background and aims: Overall obesity has recently been established as an independent risk factor for critical illness in patients with coronavirus disease 2019 (COVID-19). The role of fat distribution and especially that of visceral fat, which is often associated with metabolic syndrome, remains unclear. Therefore, this study aims at investigating the association between fat distribution and COVID-19 severity.

Methods: Thirty patients with COVID-19 and a mean age of 65.6 ± 13.1 years from a level-one medical center in Berlin, Germany, were included in the present cross-sectional analysis. COVID-19 was confirmed by polymerase chain reaction (PCR) from nasal and throat swabs. A severe clinical course of COVID-19 was defined by hospitalization in the intensive care unit (ICU) and/or invasive mechanical ventilation. Fat was measured at the level of the first lumbar vertebra on routinely acquired low-dose chest computed tomography (CT).

Results: An increase in visceral fat area (VFA) by ten square centimeters was associated with a 1.37-fold higher likelihood of ICU treatment and a 1.32-fold higher likelihood of mechanical ventilation (adjusted for age and sex). For upper abdominal circumference, each additional centimeter of circumference was associated with a 1.13-fold higher likelihood of ICU treatment and a 1.25-fold higher likelihood of mechanical ventilation.

Conclusions: Our proof-of-concept study suggests that visceral adipose tissue and upper abdominal circumference specifically increase the likelihood of COVID-19 severity. CT-based quantification of visceral adipose tissue and upper abdominal circumference in routine chest CTs may therefore be a simple tool for risk assessment in COVID-19 patients.

© 2020 Elsevier Inc. All rights reserved.

1. Introduction

In the context of the current unprecedented health crisis due to the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), evidence has emerged suggesting that obesity might aggravate the course of coronavirus disease 2019 COVID-19 [1,2]. However, previous research has focused exclusively on an increased individual body mass index (BMI) as a risk factor for severe COVID-19 without distinguishing between subcutaneous and visceral adipose tissue.

Apart from overall obesity, body fat distribution is an important risk factor for cardiometabolic outcome [1,2]. Visceral adipose tissue is often associated with metabolic syndrome, conferring an increased risk of cardiovascular disease and type 2 diabetes mellitus with subsequent higher morbidity [1,2]. Furthermore, although BMI is currently the most commonly used indicator for assessing overweight/obesity in adults and has high specificity, it is influenced by sex and age and has an inherently low sensitivity for identifying excess fat mass [3]. Furthermore, BMI-based measures cannot distinguish between visceral and subcutaneous fat. Here, computed tomography (CT) with noninvasive postprocessing tools enables the differentiation and quantification of visceral and subcutaneous fat tissue, thus allowing reliable assessment of body fat distribution [4].

Therefore, the aim of this proof-of-concept study was to quantify the subcutaneous and visceral adipose tissue of COVID-19 patients using routinely acquired chest CT scans and to compare the results with the severity of the clinical course in terms of hospitalization with intensive care unit (ICU) treatment and/or invasive mechanical ventilation.

Abbreviations: BMI, body mass index; CAP, Canon Aquilion PRIME; COVID 19, coronavirus 19; CT, computed tomography; GEL, GE Lightspeed VCT; ICU, intensive care unit; IL-6, interleukin 6; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome corona virus 2; SFA, subcutaneous fat area; TFA, total fat area; VFA, visceral fat area.
2. Material and methods

Thirty patients with COVID-19 and a mean age of 65.6 ± 13.1 years from a level-one medical center in Berlin, Germany, were included in the present cross-sectional analysis. Patients were treated between March 27 and April 27, 2020 and inclusion criteria were: availability of a (low-dose) chest CT scan with diagnostic image quality and laboratory-confirmed COVID-19. All CT datasets were of diagnostic image quality and none of the patients had to be excluded. COVID-19 was confirmed by polymerase chain reaction (PCR) from nasal and throat swabs on the day of admission. To reduce the false negative rate, at least two repeat PCRs were performed. Additional swabs were obtained to confirm the diagnosis in patients with a positive result and in case of negative results and persisting respiratory symptoms. A severe course of COVID-19 was defined by the requirement of ICU treatment and/or mechanical ventilation. Age and sex were potential confounders, which were corrected for in statistical analysis.

This proof-of-concept study was prior approved by the local ethics committee in accordance with the local laws and regulations, including a waiver of informed consent (EA 4/140/17). It was conducted in accordance with the local laws and regulations and in accordance with the Declaration of Helsinki and Good Clinical Practice.

2.1. CT imaging protocol

CT examinations of study patients were performed on two different types of scanners: three Canon Aquilion PRIME (CAP) scanners and a GE Lightspeed VCT (GEL) scanner. A low-dose chest CT scan was performed for diagnostic purposes or to evaluate the patient's current condition on the day of admission. The CT protocol included the following imaging parameters: highest rotation time available - 0.27 s (CAP) and 0.35 s (GEL), 100 kV, automatic tube modulation between 10 and 100 mA with a noise index of 27 (CAP) and 39 (GEL), collimation of 80 × 0.5 mm (CAP) and 64 × 0.625 mm (GEL), pitch factors of 1.388 (CAP) and 1.375 (GEL). Patients were positioned supine, and nonenhanced scans in caudocranial scan direction were obtained in deep inspiration. We reconstructed 0.5 mm (CAP) and 0.625 mm (GEL) axial slices using soft tissue and lung kernels (Fc01 and Fc85 (CAP), “standard” and “lung” (GEL)) and iterative reconstruction technology (AIDR3D level “moderate” (CAP), ASIR 50% (GEL)).

2.2. Data acquisition

CT fat was measured in a fully automated fashion from chest CTs using Vital's Vitrea™ Advanced Visualization postprocessing applications (Version 7.0, Canon Medical Systems Cooperation, Otawara, Tochigi, Japan), which was designed to isolate and quantify subcutaneous and visceral fat tissue based on a single slice of non-contrast enhanced CT data. Visceral fat area (VFA), subcutaneous fat area (SFA), and total fat area (TFA) were quantified at the level of the mid of the first lumbar vertebra on clinical chest CT scans routinely acquired for COVID-19 [5,6]. Data were then exported as comma-separated values.

As outcome of interest we defined whether the patient had to be transferred to the intensive care unit and if mechanical ventilation was required. The Radiology Information System was searched to determine if the patient had to be transferred to the ICU and conventional chest radiographs were assessed to assess if patients were intubated.

Other patient information such as age, weight, or height was extracted from the DICOM headers of the CT scans, if available. If this information was missing in the DICOM headers, it was instead extracted from patient reports, resulting in no missing data on age, weight or height. BMI was calculated according to the common formula: weight (kg) / [height (m)]². Other clinical information, such as comorbidities and laboratory data, were also extracted from patient records. Regarding comorbidities, we assumed a comorbidity was not present if not mentioned in any of the patient records over the last five years. Acquired data were stored in tabular form and then exported as comma-separated values for subsequent statistical analysis.

2.3. Statistical analysis

All statistical analysis was performed using the R statistical environment (Version 4.0.0), including the “tidyverse” library [7,8]. Continuous variables were tested for normal distribution using the Shapiro-Wilk test. If normally distributed, they were expressed as mean ± standard deviation. Otherwise, they were presented as median and interquartile range (IQR). Spearman’s correlation coefficients were calculated, if correlations were assessed. The three subgroups of patients (normal ward, ICU, and mechanical ventilation) were compared using an analysis of variance with mixed models corrected for age and sex, with the imaging site as random intercept. Afterwards, post-hoc binary tests were applied to compare patients on normal wards with ICU patients and patients on wards with patients requiring mechanical ventilation. Continuous and normally distributed variables were compared with a one-tailed Student’s t-test, while the Wilcoxon rank sum test was used in case of non-normal distribution. Categorical variables were expressed as frequencies and percentages and compared using Fisher’s exact test or the Chi-squared test, as appropriate. A multivariate binomial logistic regression model was employed to analyze the relationship between severe clinical courses and quantitative CT features. 95% confidence intervals for odds ratios were calculated using bootstrapping (1000 iterations). A p-value < 0.05 was considered statistically significant.

3. Results

In the present proof-of-concept study, we analyzed chest CT images of 30 patients with confirmed SARS-CoV-2 infection. The study population had a mean age of 65.6 years ± 13.1 years and included 18 men (61.9 years ± 12.8 years) and 12 women (71.2 years ± 11.8 years, p = 0.051). A total of 43% of the patients had to be transferred to the ICU during treatment (n = 13), with men being affected more often than women (9 men vs. 4 women, p = 0.47). Seven of the 13 ICU patients required mechanical ventilation (6 men vs. 1 woman, p = 0.19). Information on height and weight was available in all cases. Tables 1 to 3 provide detailed overviews of anthropomorphic and clinical patient characteristics.

3.1. Differences between patients in the ICU and normal ward

Mean BMI of all patients was 26.4 kg/m² ± 2.9 kg/m² (men 26.0 kg/m² ± 2.24 kg/m² vs. women 26.9 kg/m² ± 3.7 kg/m²). Patients who were admitted to the ICU had a BMI of 26.8 kg/m² ± 2.1 kg/m² compared to patients who did not require ICU treatment with a BMI of 26.1 kg/m² ± 3.4 kg/m². This difference was not significant (p = 0.46).

The median VFA was 82.4 cm² (IQR 55.2 cm²). Men tended to have more visceral adipose tissue than women (95.4 cm² vs. 67.3 cm²), and the difference was statistically significant (p = 0.014). Patients admitted to the ICU had a significantly larger TFA compared to patients in the normal ward. When looking at the different fat compartments, it was particularly conspicuous that ICU patients had a significantly larger VFA (96.9 cm² ± 33.5 cm²) compared to patients in the normal ward (70.0 cm² ± 28.2 cm², p = 0.031). Furthermore, patients requiring mechanical ventilation had a significantly larger VFA than patients who could breathe freely (ICU with mechanical ventilation: 124.2 cm² vs. ICU and free breathing: 96.6 cm² vs. normal ward and free breathing: 70.0 cm², p = 0.006) (see Fig. 1 for patient case examples). CT-derived upper abdominal circumference also significantly differed between patients in ICU (107.0 cm ± 8.3 cm) and patients on the normal ward (98.2 cm ± 8.0 cm, p = 0.009) and similarly between patients requiring mechanical ventilation (109.7 cm ± 7.6 cm) and patients without mechanical ventilation (103.8 ± 8.6, p = 0.008).
Table 1
Demographic and clinical patient characteristics.

| Characteristic                   | All patients (n = 30) | BMI groups | p     | Age groups | p     |
|----------------------------------|-----------------------|------------|-------|------------|-------|
| Male/female sex – No.            |                       | 18/12      |       |            |       |
| Age – years                      |                       | 7/4        | 11/8  | 1/1        |       |
| BMI – kg/m²                      | 65.6 ± 13.1           | 68.8 ± 12.8| 63.7 ± 12.2| 0.96   | 25.6 IQR 2.7 | 27.3 IQR 2.4 | 26.3 IQR 2.1 | 0.99 |
| Former or current smoker – No.   | 4                     | 3          | 1     | 0.13       | 0     | 1     | 3     | 1     |
| Coexisting disorders             |                       |            |       |            |       |
| Any – No.                        | 19                    | 7          | 12    | 1          | 2     | 5     | 12    | 0.87 |
| Hypertension – No.               | 15                    | 4          | 11    | 0.45       | 1     | 4     | 10    | 0.75 |
| Diabetes – No.                   | 5                     | 2          | 3     | 1          | 0     | 1     | 4     | 1     |
| Coronary artery disease – No.    | 5                     | 3          | 2     | 0.33       | 0     | 0     | 5     | 0.27 |
| Heart failure – No.              | 2                     | 1          | 1     | 0          | 0     | 2     | 1     |       |
| COPD – No.                       | 3                     | 3          | 0     | 0          | 1     | 0     | 3     | 0.71 |
| Bronchial asthma – No.           | 3                     | 3          | 0     | 0.28       | 0     | 0     | 3     | 0.01 |
| Chronic renal disease – No.      | 2                     | 2          | 0     | 0.013      | 0     | 0     | 2     | 1     |
| Active malignancy – No.          | 3                     | 3          | 0     | 0.04       | 1     | 0     | 2     | 0.46 |

This table provides an overview of demographic and clinical patient characteristics. Values for age and BMI are presented as mean ± standard deviation if normally distributed and as median and interquartile range (IQR) if not. P-values were obtained with Fisher tests for the count variables age and BMI and with ANOVA for all other variables. Abbreviations: No.: number, BMI: body mass index, SD: standard deviation, IQR: interquartile range.

Table 2
Fat measures and laboratory findings.

| Characteristic                   | All patients (n = 30) | BMI groups | p     | Age groups | p     |
|----------------------------------|-----------------------|------------|-------|------------|-------|
| Total fat area (10 cm²)          | 15.1 IQR: 7.6         | 12.8 ± 4.9 | 15.7 IQR: 9.7 | 0.05 | 12.6 ± 7.09 | 26.0 ± 13.4 | 15.0 IQR: 4.6 | 0.65 |
| Subcutaneous fat area (10 cm²)   | 6.2 IQR: 4.8          | 5.1 ± 12.0 | 8.4 IQR: 7.3 | 0.03 | 5.2 ± 3.6 | 6.2 IQR: 21.3 | 6.3 IQR: 3.6 | 0.64 |
| Visceral fat area (10 cm²)       | 8.2 IQR: 5.5          | 7.7 ± 3.6 | 8.8 IQR: 5.3 | 0.40 | 7.4 ± 3.8 | 10.8 SD: 1.6 | 6.6 IQR: 4.8 | 0.86 |
| Upper abdominal circumference (cm)| 102.5 ± 8.9          | 97.8 ± 7.5 | 105.3 ± 8.6 | 0.03 | 102.2 ± 3.7 | 110.4 ± 5.3 | 99.7 ± 9.1 | 0.13 |
| C-reactive protein (mg/dL)       | 63 IQR: 105.3         | 60 IQR: 97 | 96.1 ± 73.3 | 0.30 | 132.1 ± 122 | 103.2 ± 76.9 | 62 IQR: 92.8 | 0.13 |
| White-cell count – per (10³/μL)| 6.2 ± 2.7             | 5.4 ± 2.6 | 6.6 ± 2.8 | 0.39 | 5.0 ± 3.5 | 7.1 ± 3.0 | 5.6 IQR: 2.7 | 0.97 |
| Lymphocyte count – per (10³/μL) | 0.87 IQR: 0.62        | 0.77 IQR: 0.54 | 0.96 IQR: 0.63 | 0.53 | 1.1 ± 0.7 | 1.4 IQR: 2.96 | 0.8 IQR: 0.48 | 0.38 |
| Creatinine (mg/dL)               | 0.91 IQR: 0.32        | 1.02 IQR: 1.08 | 0.9 IQR: 0.26 | 0.78 | 0.78 ± 0.17 | 1.0 IQR: 0.22 | 0.99 IQR: 0.38 | 0.31 |

This table shows the distribution of fat measures and laboratory findings across different BMI and age groups. Values are presented as mean ± standard deviation if normally distributed and as median and interquartile range (IQR) if not. P-values were obtained with ANOVA for all columns. Abbreviations: IQR: interquartile range, BMI: body mass index.

Table 3
In-hospital courses of COVID-19 in the 30 study patients.

| Characteristic                   | All patients (n = 30) | BMI groups | p     | Age groups | p     |
|----------------------------------|-----------------------|------------|-------|------------|-------|
| Mortality – No.                  | 2                     | 2          | 0     | –          | 0     | 1     | 1     | –     |
| Normal ward – No.                | 17                    | 8          | 9     | 0.26       | 2     | 2     | 13    | 0.21 |
| ICU – No.                        | 13                    | 3          | 10    | 0.26       | 2     | 5     | 6     | 0.21 |
| ICU with mechanical ventilation  | 7                     | 2          | 5     | 1          | 1     | 3     | 3     | 0.39 |
| Number of days in ICU – No.      | 13.2 ± 10.2           | 4*         | 14.2 ± 10.3 | – | 19; 7** | 4 IQR 7.3 | 15.3 ± 8.3 | – |
| ARDS – No.                       | 5                     | 2          | 3     | 1          | 0     | 2     | 3     | 0.61 |

This table provides an overview of in-hospital courses of COVID-19, including mortality, number of patients in the normal ward, intensive care unit (ICU), and ICU with intubation. Also provided is information on the number of days in ICU and on patients with ARDS. The number of ICU days is given as mean ± standard deviation if the values were normally distributed in the respective subgroup and as median and interquartile range (IQR) if not. We used Fisher tests to calculate p-values for all count variables (mortality, normal ward, ICU, ICU with mechanical ventilation and ARDS) and ANOVA for group comparison regarding the number of days on the ICU. Abbreviations: No.: number, ICU: intensive care unit, ARDS: acute respiratory distress syndrome, BMI: body mass index, SD: standard deviation, IQR: interquartile range.

* The number of days in the ICU was missing for two patients, as they were transferred to another site.

** Only two patients were in the ICU in this subgroup.

Differences in SFA between patients on the normal ward vs. ICU or patients with vs. without mechanical ventilation were also significant (p = 0.039), but with only low statistical power (0.38). The differences in the various fat tissue measurements and BMI between patient groups are summarized in Table 4. Fig. 2 provides an overview of the distribution of the different BMI and fat measures.

3.2. Association between BMI and fat area measurements

VFA and BMI showed a moderate correlation with a correlation coefficient of r = 0.53 (95% CI 0.40–0.73, p < 0.001). It is noteworthy that the correlation was stronger for men than for women (r = 0.59 vs. r = 0.52), CT-derived upper abdominal circumference and BMI also showed a moderate correlation with a correlation coefficient of r = 0.59 (95% CI 0.41–0.78, p < 0.001). Again, men showed a slightly stronger correlation between BMI and CT-derived upper abdominal circumference compared to women (r = 0.62 vs. r = 0.58).

3.3. Association between fat area measurements and COVID-19 severity

As VFA and CT-derived upper abdominal circumference differed significantly between patients who required ICU treatment and/or
mechanical ventilation and patients who did not require ICU treatment or mechanical ventilation, a logistic regression analysis was conducted. Two models each were constructed for VFA and CT-derived upper abdominal circumference, the first unadjusted for any confounder, the second adjusted for age and sex. Table 5 gives an overview of the odds ratios derived from logistic regression analysis. An increase in VFA by 10 square centimeters was associated with a higher likelihood of ICU treatment and a higher likelihood of mechanical ventilation. The odds ratio, as derived from the model adjusted for age and sex, was 1.37 (95% CI 1.07–1.89) regarding ICU treatment. This means that patients were 1.37 times more likely to require ICU treatment than patients with 10 cm² less VFA. Similarly, those patients were also 1.32 (95% CI 1.04–1.91) times more likely to require mechanical ventilation compared to patients with 10 cm² less VFA.

For CT-derived upper abdominal circumference, each additional centimeter of circumference was associated with a 1.13-fold (95% CI 1.02–1.3) higher likelihood of ICU treatment and a 1.25-fold (95% CI 1.05–1.68) higher likelihood of mechanical ventilation.

4. Discussion

In the present proof-of-concept study, subcutaneous and visceral adipose tissue was automatically quantified in routinely acquired chest CT scans of COVID-19 patients at the level of the first lumbar vertebra using a post-processing application, which was not previously validated for fat measurements in COVID-19 patients. Apart from the total fat area, we identified visceral adipose tissue and CT-derived upper abdominal circumference as significant indicators of severe courses of COVID-19, while BMI was not an indicator in our analysis. A severe course was assumed when a patient needed ICU treatment and/or mechanical ventilation.

In 2016, the World Health Organization estimated that 1.9 billion adults were overweight and of these, over 650 million were obese [9]. Overall obesity is a state of low-grade systemic inflammation, which contributes to the development of metabolic diseases, such as dyslipidemia or type 2 diabetes mellitus, and may modify immune responses, making the immune system more susceptible to infection.
This could also play an important role in the pathogenesis of respiratory disorders [11]. In the context of influenza virus infection, obesity has been suggested to impair memory CD8+ T cell responses to infection, resulting in more severe lung pathology and higher mortality [12]. Particularly central obesity with intra-abdominal deposition of visceral fat tissue has been closely linked to cardiometabolic disorders [13]. Visceral adipose tissue, known to be more metabolically active than subcutaneous adipose tissue, has unique

---

**Table 5**

Multivariate logistic regression analysis for ICU treatment and mechanical ventilation.

| Variable                                      | Odds ratio | 95% CI     | Outcome          |
|-----------------------------------------------|------------|------------|------------------|
| Unadjusted for age and sex                    |            |            |                  |
| Visceral fat area (per 10 cm²)                | 1.36       | 1.08–1.86  | Patient in ICU   |
| Upper abdominal circumference (per 1 cm)      | 1.13       | 1.03–1.29  | Patient in ICU   |
| Total fat area (per 10 cm²)                   | 1.11       | 1.02–1.28  | Patient in ICU   |
| Visceral fat area (per 10 cm²)                | 1.30       | 1.05–1.68  | Mechanical ventilation |
| Upper abdominal circumference (per 1 cm)      | 1.17       | 1.04–1.57  | Mechanical ventilation |
| Total fat area (per 10 cm²)                   | 1.08       | 0.99–1.19  | Mechanical ventilation |
| Adjusted for age and sex                      |            |            |                  |
| Visceral fat area (per 10 cm²)                | 1.37       | 1.07–1.89  | Patient in ICU   |
| Upper abdominal circumference (per 1 cm)      | 1.13       | 1.02–1.29  | Patient in ICU   |
| Total fat area (per 10 cm²)                   | 1.13       | 1.03–1.29  | Patient in ICU   |
| Visceral fat area (per 10 cm²)                | 1.32       | 1.04–1.91  | Mechanical ventilation |
| Upper abdominal circumference (per 1 cm)      | 1.25       | 1.05–1.68  | Mechanical ventilation |
| Total fat area (per 10 cm²)                   | 1.28       | 1.06–1.80  | Mechanical ventilation |

This table provides the odds ratios for ICU treatment and mechanical ventilation, derived from multivariate logistic regression analysis, unadjusted and adjusted for age and sex. Abbreviations: CI: confidence interval, ICU: intensive care unit.
endocrine functions and secretes a variety of adipokines and pro-inflammatory cytokines, including TNF, C-reactive protein, interleukin 6 (IL-6), and leptin [12,14]. Apart from insulin resistance and metabolic syndrome, elevated IL-6 levels are known to be related to chronic inflammatory airways disease, and recent studies report higher levels of IL-6 in COVID-19 non-survivors [15,16]. Early findings from Italy suggest that IL-6 receptor inhibition by administration of the monoclonal antibody tocilizumab might improve respiratory function in COVID-19-related acute respiratory distress syndrome [17]. In addition, leptin was previously found to be related to airway reactivity, and initial findings suggest that leptin levels are elevated in COVID-19 patients with more severe pulmonary inflammation [18,19].

With the shift of COVID-19 epicenters to Europe and now especially North and South America, the impact of obesity on COVID-19 may gain in importance, as these two continents have some of the highest prevalence of obesity worldwide, with obesity taking on epidemic proportions [20]. While previous investigators already identified overall obesity as a risk factor for severe courses of COVID-19, they only used BMI to measure obesity [21–24]. Compared to recent COVID-19 studies from New York and Lille [24,25], which used BMI as a measure of obesity, our ICU patients were of similar age (65.6 ± 13.1 years) as the patients from New York (median 67, ICR 56–77 years), while patients from Lille were younger (median 60, ICR 51–70 years) [26]. Regarding median BMI, the Lille center found that COVID-19 patients with a BMI ≥ 35 kg/m² required mechanical ventilation significantly more often than COVID-19 patients with a BMI below 25 kg/m² [24]. In a New York patient population, especially a BMI ≥ 40 kg/m² was identified to be among the factors most strongly associated with hospitalization of COVID-19 patients [25]. Another study from New York by Palaiodimos et al. examined a minority-predominant population and found that severe obesity was independently associated with a higher in-hospital mortality [27]. Zheng et al. reported patients with metabolic associated fatty liver disease and obesity (BMI > 25 kg/m²) to have a 6-fold higher risk for a severe course of COVID-19 [2]. By comparison, we found a more than 1.37-fold higher likelihood of ICU treatment and a more than 1.32-fold higher likelihood of mechanical ventilation for an increase in VFA by 10 cm² (adjusted for age and sex).

A current study by Deng et al. found that obesity could also increase severe courses of COVID-19 in younger patients, especially in those with damages of liver and kidneys [28]. Kass et al. also reported, that obesity could shift severe COVID-19 to younger ages after examining the correlation between BMI and age in COVID-19 patients admitted to the ICU at different university hospitals in the United States [29]. Most recently, Stefan et al. underlined the importance of measuring anthropometrics and metabolic parameters, such as BMI, waist and hip circumferences and levels of glucose and insulin, in addition to the evaluation of standard hospital parameters in order to improve individual risk assessment of COVID-19 patients [1].

It should be noted that the utility of BMI in assessing obesity depends on the assumption of a close correlation of anthropomorphic measures with direct measures of obesity, such as total body fat or visceral and subcutaneous adipose tissue [24]. Here, several studies suggest that, for the same BMI, the amount of body fat is heavily influenced by age and sex, as women tend to have more fat than men with the same BMI, while older persons tend to have more body fat than younger persons with the same BMI [30,31]. This is in line with our correlation coefficient of 0.56 for VFA and BMI and the consistently moderate correlation coefficients reported in the literature, ranging from 0.61 to 0.71 after adjustment for age [26,32,33].

By using CT-based quantification of the visceral and subcutaneous adipose tissue, we chose a more comprehensive approach to measure potential obesity, which allowed us to separately determine different fat compartments such as the subcutaneous and visceral fat area. This is essential as body fat distribution was previously established as an independent risk factor for cardiometabolic outcomes in the general population, next to obesity [2]. Although the post-processing application used in the present study (Vitream) was not previously validated for fat measurement in COVID-19 patients, it has been validated for abdominal fat measurement by using cryosection photographs and CT images from the NIH Visible Human Project [34,35]. In addition, it was reported that visceral fat areas obtained from a single slice and waist circumference obtained at the level of the umbilicus (approximately L4 or L5) were highly correlated to the total visceral fat volume [36,37]. Here, it has to be pointed out, that we obtained the fat measurements at the level of the first lumbar vertebra instead of the fourth or fifth vertebra, as the lower levels were not included in the chest CT scans. Kuk et al. previously investigated if the measurement site for visceral and abdominal subcutaneous adipose tissue in CT scans would alter associations with the metabolic syndrome and found no significant difference between Th12-L1, L1-2 and L4-L5 [38]. Therefore, it appears that the first lumbar vertebra (L1) may similarly be used for fat measurement. Still, our deviating measurement method (measurement at the level of L1 instead of L4/5) has to be recognized as a potential shortcoming.

In our COVID-19 population we found that - apart from TFA - VFA and CT-derived upper abdominal circumference were associated with ICU treatment and/or mechanical ventilation. Differences in SFA were also statistically significant, but with only low statistical power, while BMI did not show any significant association with severe courses of COVID-19. However, it has to be acknowledged that the mean BMI was quite low in our study population, with most of the patients being overweight, but not obese. This might explain why BMI was not a significant indicator in our patients. On the other hand, this observation highlights the importance of visceral adipose tissue as a potential indicator of COVID-19 severity in overweight patients with an increased amount of visceral fat tissue who do not meet the criterion for obesity.

To our knowledge, this is the first study that specifically identifies visceral fat and CT-derived upper abdominal circumference as potential risk factors for severe courses of COVID-19. These indicators can be determined without the need for further imaging simply by performing an automated postprocessing analysis of a standard chest CT scan, provided that it was acquired during routine diagnostic workup. However, it should be noted that a CT-based measurement is obviously not less costly than an anthropomorphic measurement of waist circumference. But other than conventional anthropomorphic measurements, CT-based measurements also allow for an assessment of the visceral and subcutaneous adipose tissue. In addition, even simple measurements, such as measurements of the waist circumference, can be more difficult to obtain in critically ill patients. Given that some COVID-19 patients are extremely ill, such easy-to-determine parameters may be of clinical relevance.

The present proof-of-concept study has several limitations: firstly, anthropomorphic measures were derived from DICOM headers or patient records and might have been reported by the patients with possible bias. Secondly, regarding comorbidities, we also extracted this information from the patient records, assuming a comorbidity was not present if not mentioned in any of the patient records over the last five years. We are aware, that this approach might lead to biased results for the presence of comorbidities. Besides there were also missing data on laboratory data. However, as this data was only provided in the sense of additional clinical information and not included in any analysis, we believe, that this does not affect the results of the present study. Thirdly, the post-processing application used for the fat measurements was not previously validated for fat measurements in COVID-19 patients. Besides, CT-based fat measurements were performed at the level of the first lumbar vertebra instead of the fourth or fifth vertebra and we used the upper abdominal circumference instead of the abdominal circumference. This may have affected the reliability of our fat measurements. Finally, a major limitation is the small sample size and the single-center cross-sectional design. Retrospective epidemiological studies in larger populations as well as autopsy studies and clinical trials with the aim to identify individuals most at risk of becoming infected or
of developing complications will be needed for a better selection of individual safety measures. Also, it will be important to determine if it is possible to employ prophylactic and therapeutic measures (e.g., treatment modulating the complement system or IL-6 secretion), and if there are long-term consequences of COVID-19 infection on the health of patients with overweight and increased amounts of adipose tissue. Finally, the pathophysiological link between obesity, overweight, visceral adipose tissue and respiratory disease will have to be further investigated.

5. Conclusions

Going beyond the recently established association between BMI-based obesity and severe courses of COVID-19, our results suggest that body fat distribution is also important, with visceral adipose tissue and CT-derived upper abdominal circumference significantly increasing the likelihood of severe courses of COVID-19. Hence, CT-based quantification of visceral adipose tissue and upper abdominal circumference might be a simple tool for risk assessment in COVID-19 patients.

CRediT authorship contribution statement

Antonia Petersen: Validation, Investigation, Data curation, Writing - original draft. Keno Bressen: Conceptualization, Methodology, Software, Formal analysis, Writing - review & editing. Jakob Albrecht: Writing - review & editing. Hans-Martin Thieß: Writing - review & editing. Janis Vahldiek: Writing - review & editing. Bernd Hamm: Resources, Writing - review & editing. Marcus R. Malkowski: Writing - review & editing. Alexandra Niehues: Investigation, Writing - review & editing. Stefan M. Niehues: Conceptualization, Methodology, Resources, Writing - review & editing. Supervision, Project administration. Lisa C. Adams: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Data curation, Writing - original draft, Visualization, Supervision, Project administration.

Declaration of competing interest

BH has received research grants for the Department of Radiology, Charité - Universitätsmedizin Berlin from the following companies and institutions: (1) Abbott, (2) Actelion Pharmaceuticals, (3) Bayer Schering Pharma, (4) Bayer Vital, (5) BRACCO Group, (6) Bristol-Myers Squibb, (7) Charite Research Organisation GmbH, (8) Deutsche Krebshilfe, (9) Dt. Stiftung für Herzforschung, (10) Essex Pharma, (11) EU Programmes, (12) FibrexMedical Inc., (13) Focused Ultrasound Foundation, (14) Focused Ultrasound Research, (15) Insightec Ltd, (16) IPSEN Pharma, (17) InSightec GmbH, (18) ISATherapeutics, (19) Keno Bressen, (20) Lilly GmbH, (21) Lundbeck GmbH, (22) MeVis Medical Solutions GmbH, (23) Nexus Oncology, (24) Novartis, (25) Parexel Clinical Research Organisation Service, (26) Perceptive, (27) Pfizer GmbH, (28) Philips, (29) Sanofi-Aventis S.A., (30) Siemens, (31) Spectrumanetics GmbH, (32) Termo Medical Corporation, (33) TNS Healthcare GmbH, (34) Toshiba, (35) UC-B Pharma, (36) Wyeth Pharma, (37) Zukunftsfond Berlin (TSB), (38) Angen, (39) AO Foundation, (40) BARD, (41) BBraun, (42) Boehringer Ingelheimer, (43) BrainGate, (44) PPD (Clinical Research Organisation), (45) CELLACT Pharma, (46) Celgene, (47) CelNovo Bio-Sciences, (48) Covance, (49) DC Deviees, Inc. USA, (50) Genymed, (51) Gilead Sciences, (52) GlaxoSmitKline, (53) ICON (Clinical Research Organisation), (54) Jansen, (55) LUX Bioseieenes, (56) MedPass, (57) Merek, (58) Mologen, (59) Nutiva, (60) Pluristem, (61) Quintiles, (62) Roche, (63) SemaheuerGmbH (Sponsoring eines Workshops), (64) Seattle Geenities, (65) Symphogen, (66) TauRx Therapeuties Ud, (67) Accovion, (68) AIO: Arbeitsgemeinschaft Internistische Onkologie, (69) ASR Advanced sleep research, (70) Astellas, (71) Theradex, (72) Galena Biopharma, (73) Chiltern, (74) PirAint, (75) Inspiremed, (76) Medronic, (77) Resplicardia, (78) Silene Therapeutics, (79) Spectrum Pharmaceuticals, (80) St Jude, (81) TEVA, (82) Theorem, (83) Abbvie, (84) Aesculap, (85) Biotronic, (86) Inventivhealth, (87) ISATherapeutics, (88) LYSARC, (89) MSD, (90) Novocure, (91) Ockham Oncology, (92) Premier-Research, (93) Psi-cro, (94) Teter-ag, (95) Winicker-Norimed, (96) Achaogen Inc., (97) ADIR, (98) AstraZenaca AB, (99) Demira Inc., (100) Euroscreen S.A., (101) Galmed Research and Development Ltd., (102) GETNE, (103) Guidant Europe NV, (104) Holaira Inc., (105) Immunomedica Inc., (106) Innate Pharma, (107) Isis Pharmaceuticals Inc., (108) Kantar Health GmbH, (109) MedImmune Inc., (110) Medpace Germany GmbH (CRO), (111) Merrimack Pharmaceuticals Inc., (112) Millenium Pharmaceuticals Inc., (113) Orion Corporation Orion Pharma, (114) Pharmacys Inc., (115) PIQUR Therapeutics Ltd., (116) Pulmox International Sàrl, (117) Servier (CRO), (118) SGS Life Science Services (CRO), and (119) Treshold Pharmaceuticals Inc. S.M. Niehues has received funding from Bayer Vital, Bracco, Gubert, Canon Medical Systems and Teleflex medical. The funding had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare that they have no conflicts of interest and did not receive any funds. There are no patents, products in development, or marketed products to declare.

Acknowledgments

MRK is grateful for support from the Deutsche Forschungsgemeinschaft (DFG, SFB 1340/1 2018, 5943/31/91). LCA is grateful for her participation in the BIH Charité – Junior Clinician and Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health.

Funding information

This research received no specific grant from any funding organisation in the public, commercial, or not-for-profit sectors.

References

[1] Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16:341–2.
[2] Zheng KI, Gao F, Wang XR, Sun QF, Pan KH, Wang TY, et al. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. Metabolism. 2020;154244.
[3] Reilly JJ, El-Hamouchi A, Diouf A, Monyeky A, Somda SA. Determining the worldwide prevalence of obesity. Lancet. 2018;391:1773–4.
[4] Rosenquist KJ, Pedley A, Massaro JM, Tchernkhes KE, Muralibh JT, Hoffmann U, et al. Visceral and subcutaneous fat quality and cardiometabolic risk. JACC Cardiovasc Imaging. 2013;6:762–71.
[5] Tong Y, Udapa JK, Torjian DA. Optimization of abdominal fat quantification on CT imaging through use of standardized anatomic space: a novel approach. Med Phys. 2014;41:063501.
[6] Lee SJ, Liu J, Yao J, Kanarek A, Summers RM, Pickhardt PJ. Fully automated segmentation and quantification of visceral and subcutaneous fat at abdominal CT: application to a longitudinal adult screening cohort. Br J Radiol. 2018;91:20170685.
[7] Team RC. A language and environment for statistical computing; 2013.
[8] Wickham H. Tidyverse: easily install and load the ‘tidyverse’. R package version. 2017;1: 2017.
[9] Hlatky MA. Obesity: an emerging threat. J Natl Black Nurses Assoc. 2018;29:36–9.
[10] Dharanand NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015;16:1017–29.
[11] Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13:633–43.
[12] Muscogiuri G, Pugliese G, Barrea L, Savastano S, Colao A. Commentary: obesity is the ‘Achilles heel’ for COVID-19? Metabolism. 2020;108:154251.
[13] Farb MG, Gokce N. Visceral adiposity: a vascular perspective. Horm Mol Biol Clin Investig. 2015;21:125–36.
[14] Zhong A, Frenkel A, Forshel A, Adjan M, Dobchuck S, Yuan J, et al. Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. Oncotarget. 2015;6:34475–93.
[15] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
[16] Park VS, Kwon HT, Hwang SS, Choi SH, Cho YM, Lee J, et al. Impact of visceral adiposity measured by abdominal computed tomography on pulmonary function. J Korean Med Sci. 2011;26:771–7.
[17] Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnessi L. Obesity and SARS-CoV-2: a population to safeguard. Diabetes Metab Res Rev. 2020:e3325 Online ahead of print.

[18] Sideleva O, Suratt BT, Black KE, Pratley RE, Forgione P, et al. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. Am J Respir Crit Care Med. 2012;186:598–605.

[19] Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020 Ahead of print.

[20] Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–89.

[21] Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of obesity with disease severity among patients with COVID-19. Obesity. 2020;28:1200–4.

[22] Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity. 2020;28(6):1005www.obesityjournal.org.

[23] Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis. 2020 Online ahead of print.

[24] Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020;28(7):1195–9.

[25] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.

[26] Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL, et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity (Silver Spring). 2007;15:2984–93.

[27] Despres JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: the Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol. 2000;20:1932–8.

[28] Deng M, Qi Y, Deng L, Wang H, Xu Y, Li Z, et al. Obesity as a potential predictor of disease severity in young COVID-19 patients: a retrospective study. Obesity (Silver Spring). 2020.

[29] Kashi DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020;395:1544–5.

[30] Demerath EW, Sun SS, Rogers N, Lee M, Reed D, Choh AC, et al. Anatomical patterning of visceral adipose tissue: race, sex, and age variation. Obesity (Silver Spring). 2007;15:2984–93.

[31] Liu Y, Guo D, Niu Z, Wang Y, Fu G, Zhou Y, et al. Prediction of the risk of laparoscopy-assisted gastrectomy by comparing visceral fat area and body mass index. Gastroenterol Res Pract. 2018;2018:1359625.

[32] Fox CS, Massaro JM, Hoffman U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.

[33] Winfield RD, Mellnick VM, Chamieh J, Mohr E, Tan WH, Ramirez R, et al. Adipose tissue location and contribution to postinjury hypercoagulability. J Trauma Acute Care Surg. 2016;81:79–85.

[34] Nguyen GK, Mellnick VM, Yim AK, Salter A, Ippolito JE. Synergy of sex differences in visceral fat measured with CT and tumor metabolism helps predict overall survival in patients with renal cell carcinoma. Radiology. 2018;287:884–92.

[35] Yoshizumi T, Nakamura T, Yamane M, Islam AH, Menju M, Yasunari K, et al. Abdominal fat: standardised technique for measurement at CT. Radiology. 1999;211:283–6.

[36] Nemoto M, Yerun Y, Masutani Y, Nomura Y, Hanaoka S, Miki S, et al. Development of automatic visceral fat volume calculation software for CT volume data. J Obes. 2014;2014:495084.

[37] Kuk JL, Church TS, Blair SN, Ross R. Does measurement site for visceral and abdominal subcutaneous adipose tissue alter associations with the metabolic syndrome? Diabetes Care. 2006;29:679–84.